ACTIVE_NOT_RECRUITING

MRI Following Stereotactic Radiosurgery (SRS) for Brain Metastases

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to test whether an additional magnetic resonance image (MRI) sequence can improve the ability to distinguish radiation damage from tumor recurrence in participants with brain metastasis who have previously been treated with stereotactic radiosurgery (SRS).

Official Title

Diagnostic Accuracy of Delayed MRI Contrast Enhancement Characteristics and Radiation Necrosis Following Stereotactic Radiosurgery (SRS) for Brain Metastases

Quick Facts

Study Start:2021-07-19
Study Completion:2027-03-19
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:ACTIVE_NOT_RECRUITING

Study ID

NCT04246879

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Adult patients, age ≥18
  2. * Metastatic malignancy with at least 1 brain metastasis previously treated with SRS
  3. * Patients may have also received whole brain radiation therapy (WBRT) for management of brain metastatic disease but this is not required for study participation
  4. * Patients must have been diagnosed with a metastatic solid tumor of any histological type except small cell lung cancer (SCLC), or lymphoma.
  5. * Radiographic progression on post-SRS imaging at previously treated SRS site(s)
  6. * Must be a candidate for brain surgery as determined by treating neurosurgeon and/or anesthesia team
  7. * Patients must sign study-specific informed consent prior to study entry
  1. * Poor surgical candidate as determined by treating neurosurgeon and/or anesthesia team
  2. * Unable to undergo contrasted MRI (e.g. incompatible medical device, inadequate renal function per standard institutional clinical protocol, contrast allergy)
  3. * Small cell lung cancer (SCLC) or lymphoma histology

Contacts and Locations

Principal Investigator

Scott Floyd, M.D. Ph.D.
PRINCIPAL_INVESTIGATOR
Duke Health

Study Locations (Sites)

Duke University Health System
Durham, North Carolina, 27710
United States

Collaborators and Investigators

Sponsor: Duke University

  • Scott Floyd, M.D. Ph.D., PRINCIPAL_INVESTIGATOR, Duke Health

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-07-19
Study Completion Date2027-03-19

Study Record Updates

Study Start Date2021-07-19
Study Completion Date2027-03-19

Terms related to this study

Keywords Provided by Researchers

  • Laser Interstitial Thermal Therapy (LITT)
  • Stereotactic radiosurgery (SRS)
  • Magnetic resonance image (MRI)

Additional Relevant MeSH Terms

  • Brain Metastases